Navigation Links
Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus

-LymphoStat-B(R) significantly reduced signs and symptoms of SLE disease at 52 Weeks and demonstrated durable clinical and biological activity at 76 weeks-

ROCKVILLE, Md., June 14, 2007 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. today announced the presentation of Phase 2 trial data demonstrating that LymphoStat-B(R) (belimumab) significantly reduced disease activity across multiple clinical measures, was well tolerated and improved quality of life in patients with active systemic lupus erythematosus (SLE). The 52-week and 76-week results of the Phase 2 study were the subject of an oral presentation today in Barcelona at the annual congress of the European League Against Rheumatism (EULAR).

"A number of clinical measures used in the Phase 2 study demonstrate that LymphoStat-B produced significant improvements in disease activity in patients with serologically active SLE," said Ellen Ginzler, M.D., Professor of Medicine and Chief of Rheumatology at the Downstate Medical Center, State University of New York (SUNY) in Brooklyn. "At Week 52, we saw significant reductions in SLE disease activity as measured by the SELENA SLEDAI and BILAG indices and the Physician's Global Assessment, as well as the patient response rate chosen as the primary efficacy endpoint of the Phase 3 trials. Continued improvements were observed from Week 52 through Week 76 in the 24-week extension phase of the trial."

Dr. Ginzler noted that reductions observed in activated B cells and anti- dsDNA autoantibodies, as well as the improvements observed in health-related quality of life, were associated with therapeutic response. No increase in infections or infectious events was observed over time. "We look forward to continuing the evaluation of LymphoStat-B as a potential treatment for SLE in the Phase 3 trials that are now underway," she said.

Of the patients who completed 52 weeks of treatment in this randomize
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Testing for Human Papillomavirus
2. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
3. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
4. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
5. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
6. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
7. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
8. NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans
9. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
10. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
11. Human Genome Sciences Announces Positive Final Results Of Phase 2b Trial of Albuferon
Post Your Comments:
(Date:4/17/2015)... WASHINGTON , April 17, 2015 ... (PhRMA) honored 13 employees from 12 biopharmaceutical companies ... extraordinary efforts in policy advocacy and community service. ... for Health Champion Awards were created by the ... only excelled in their careers, but have also ...
(Date:4/17/2015)... , Apr. 16, 2015 Research and Markets ... addition of the "The Corporate Reputation of ... Global Edition " report to their offering. ... Patient Perspective, is now in its fourth edition. ... published early 2015). For each annual Corporate Reputation ...
(Date:4/17/2015)... -- Bionomics Limited (ASX:BNO, ADR:BMICY), a biopharmaceutical company focused ... the treatment of cancer and diseases of the central ... three of its most advanced oncology programs at the ... Annual Meeting being held from April 18-22, 2015 ... The presentation on the BNC105 program describes ...
Breaking Medicine Technology:PhRMA Applauds 2015 We Work For Health Champion Award Winners 2PhRMA Applauds 2015 We Work For Health Champion Award Winners 3The Corporate Reputation of Pharma - The Global Patient Perspective in 2014 2Bionomics Showcases Oncology Drug Development Programs at 2015 AACR Annual Meeting 2Bionomics Showcases Oncology Drug Development Programs at 2015 AACR Annual Meeting 3Bionomics Showcases Oncology Drug Development Programs at 2015 AACR Annual Meeting 4Bionomics Showcases Oncology Drug Development Programs at 2015 AACR Annual Meeting 5
... HONG KONG, Jan. 5, 2011 SuperNova Diagnostics®, Inc., ... health applications, announced today that Neil J. Campbell, president ... conjunction with the J.P. Morgan Healthcare Conference in San ... be given at the Parc 55 Wyndham Hotel on ...
... Jan. 5, 2011 / PRNewswire / -- Nektar ... Officer, Howard W. Robin, is scheduled to present at the ... at the Westin St. Francis Hotel on Tuesday, January 11, ... will be accessible via a Webcast through a link posted ...
Cached Medicine Technology:SuperNova Diagnostics® to Present at Biotech Showcase™ 2011 During J.P. Morgan Healthcare Conference January 10-13 2Nektar Therapeutics' President and CEO, Howard W. Robin, to Present at the 29th Annual J.P. Morgan Healthcare Conference in San Francisco, CA 2
(Date:4/18/2015)... YORK (PRWEB) April 18, 2015 Review ... are hosting a ‘Strategies for Success’ program for cataract ... Surgeons meeting in San Diego, where eye surgeon Jeffrey ... for this invitation-only event. Dr. Martin is the Managing ... Review of Ophthalmology chose Dr. Martin to lead this ...
(Date:4/18/2015)... 2015 Patients who undergo radiation for ... later in life, but the disease is likely to ... unrelated to radiation. Surviving Mesothelioma has just posted the ... Click here to read it now. , Scientists ... of 45 patients who had both a hematologic cancer ...
(Date:4/18/2015)... On April 14th, 2015, Symantec released Volume ... say, “exposes a tactical shift by cyberattackers.” With everything from ... in 2014 - almost a million a day - to ... identified and patched by prominent manufacturers – as long as ... in a digital world can be fraught with peril, and ...
(Date:4/18/2015)... 2015 French physician and gastronome Anthelme ... when he uttered, “Tell me what you eat, and ... to cope with stress or sadness has often been ... indicates otherwise. Data collected from their Emotional Eating ... emotional eating, but for different reasons. , Collecting data ...
(Date:4/17/2015)... April 17, 2015 ERGO-Pedic Products, LLC, ... introducing two new products to help a broader range ... pain relief are the second most common visitors to ... product, designed specifically to help relieve sitting pain. Then, ... and thousands of happy customers later, we began getting ...
Breaking Medicine News(10 mins):Health News:Dr. Jeffrey Martin Invited to Share Latest Breakthroughs in Cataract Care During Roundtable Discussion at National 2015 ASCRS Meeting In San Diego 2Health News:New Study Examines Relationship Between Radiation for Hematologic Cancers and Development of Mesothelioma, According to Surviving Mesothelioma 2Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 2Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 3Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 4Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 5Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 2Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 3Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 4Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 5Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 6Health News:Seat Cushion Company Credits Customer Driven Design For Two New Products 2
... birth but develop accelerated head growth between six and ... onset of many behaviors that enable physicians to diagnose ... University of Washingtons Autism Center., The study also indicates ... have the early onset form of autism as well ...
... Store,s Gift of Mobility Fulfills Dreams of Terminally Ill,Stage Performer, ... his life in the public eye - whether he was ... or appearing in,television commercials. But two years ago, cancer robbed ... past year. To fulfill his,dream to get outside again, The ...
... BOCA RATON, Fla., Jan. 30 Spirit of ... bidding for the Spirit of Women,Celebrity Red Shoe ... will benefit several health,organizations, including the National Stroke ... for auction February 5,through February 14 were autographed ...
... Web address on all TV ads to report adverse,reactions, ... ads that sell the "good news" about prescription drugs,but ... on a petition to the FDA demanding the agency ... medications., The citizens, petition requests the Food and ...
... LANSING, Jan. 30 A report issued today ... policy consultancy,based in Washington, D.C., confirms that Blue ... million to the people of Michigan in 2007 ... to improve access to,health coverage at affordable prices. ...
... known to doctors as a hormone that boosts red-blood-cell production. ... PhD, an ophthalmologist at Children,s Hospital Boston, shows it also ... The findings not only add a new function to the ... prescribing it to patients with diseases affected by abnormal blood-vessel ...
Cached Medicine News:Health News:Accelerated head growth can predict autism before behavioral symptoms start 2Health News:Former Actor has Mobility Restored With Power Wheelchair Gift From The Scooter Store 2Health News:Celebrities Encourage Women to Take Steps for Heart Health Through Online Red Shoe Charity Auction 2Health News:Petition Asks FDA to Make it Easier for Patients to Report Side Effects from Prescription Drugs 2Health News:Examination by National Expert Shows Blue Cross Blue Shield of Michigan's Social Mission Contributions Totaled at Least $391 Million in 2007 2Health News:Examination by National Expert Shows Blue Cross Blue Shield of Michigan's Social Mission Contributions Totaled at Least $391 Million in 2007 3Health News:Anemia treatment may be a double-edged sword 2Health News:Anemia treatment may be a double-edged sword 3
... MLA 750 is an ideal backup ... Photometric end point detection means there ... no electrodes are inserted into the ... impossible. The MLA 750 operates with ...
... Advance can reduce costs and ... With its superior ACL technology, ... to use coagulation analyzer that ... the protective transparent cover increases ...
HemoSite meter can be used to measure the effects of transfusion or the treatment of deficiency states. It is fast, easy, convenient and discrete....
... StatSite MHgb test system ... battery-operated, dedicated hemoglobin test system ... offices, public health clinics, blood ... truly portable system is designed ...
Medicine Products: